Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 18 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 15 16 17 18 presentations: 1 to 25 of 435
Gene dysregulation in cancer: The view from chromosome neighborhoods
Richard A. Young
MIT Whitehead Inst. for Biomed. Research, Cambridge, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
Histone modifications and gene expression in cancer
Scott A. Armstrong
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
ATP-dependent chromatin remodeling complexes in human cancer
Cigall Kadoch
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
Enhancer reprogramming during cancer progression
Christopher R. Vakoc
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
Somatic HLA mutations and neoantigen identification for immunotherapy analyses
Sachet A Shukla
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Dynamics of genomic and neoantigen landscape during immune checkpoint blockade
Valsamo Anagnostou
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Integrative clinical and genomic analysis of solid tumors treated with immune checkpoint blockade
Jeffrey E Hammerbacher
Icahn School Of Medicine At Mount Sinai, New York, NY, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Infiltrating immune cell signatures and genomic determinants of immune recognition in diverse tumors
Ash A. Alizadeh
Stanford Univ., Stanford, CA, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Invited Speaker
Daniel S. Chen
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2017 on April 2, 2017 7:00 AM-8:00 AM
Tumor-associated myelomonocytic cells as therapeutic targets
Alberto Mantovani
Humanitas University, Rozzano, Milano, Italy
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
Macrophage-targeted cancer immunotherapy
Carola Ries
Roche Innovation Center Munich, Penzberg, Germany
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
Reprogramming the tumor microenvironment to improve responses to therapy
David G. Denardo
Washington Univ. School of Medicine, Saint Louis, MO, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
Discovery of GDC-0077, a highly isoform selective inhibitor of PI3Kα that promotes selective loss of mutant-p110α
Steven T Staben
Genentech, Inc, Emerald Hills, CA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
SGN-2FF: A novel small molecule inhibitor of fucosylation with preclinical antitumor activity through multiple immune mechanisms
Stephen C. Alley
Seattle Genetics, Inc., Bothell, WA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
PRMT5 inhibitor: Novel clinical agent with therapeutic potential in heme and solid cancers
Olena Barbash
GlaxoSmithKline, Collegeville, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models
Dirk Brehmer
Janssen R&D, Beerse, Belgium
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by PDGFRA and KIT mutations
Erica K. Evans
Blueprint Medicines, Cambridge, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Invited Speaker
Dihua Yu
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2017 on April 3, 2017 7:00 AM-8:00 AM
Invited Speaker
Jody S. Rosenblatt
Huntsman Cancer Institute, Salt Lake City, UT, United States
from AACR Annual Meeting 2017 on April 3, 2017 7:00 AM-8:00 AM
MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease
Hope S Rugo
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, United States
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
Fabrice Andre
Institut Gustave Roussy, Université Paris-Sud, Villejuif, France
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Discussant
Filipa Lynce
Georgetown University, Washington, DC, United States
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients with RAS mutant solid tumors
Geoffrey I. Shapiro
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
Geoffrey I. Shapiro
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Discussant
Timothy A. Yap
Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
<< first | < prev page: of 18 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 15 16 17 18 presentations: 1 to 25 of 435